BET 1: levosimendan in septic shock.
A shortcut review was carried out to establish whether levosimendan improves outcome in septic shock. Eight studies were directly relevant to the question. The author, date and country of publication, patient groups studied, study type, relevant outcomes, results and study weaknesses of these papers are tabulated. The clinical bottom line is that there is as yet no evidence that levosimendan reduces mortality from septic shock. The LeoPARDS trial may change that.
Jonathon
J
Coates
Steve
S
Mathieu
D002316:Cardiotonic Agents / Q000627:therapeutic use*; D055416:Evidence-Based Emergency Medicine; D006801:Humans; D006835:Hydrazones / Q000627:therapeutic use*; D011724:Pyridazines / Q000627:therapeutic use*; D012772:Shock, Septic / Q000188:drug therapy*; D000077464:Simendan
D002316:Cardiotonic Agents; D006835:Hydrazones; D011724:Pyridazines; D000077464:Simendan